Zhou Yu, Li Qian, Meng Heng-Xing, Wang Ya-Fei, Yu Zhen, Qiu Lu-Gui
Institute of Hematology & Blood Diseases Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin 300020, China.
Zhonghua Nei Ke Za Zhi. 2005 Jan;44(1):46-9.
To evaluate the expression and clinical significance of early differentiation antigens of hematopoietic cells CD(34), CD(90) and CD(133) in acute leukemia (AL).
The expression of CD(34), CD(90) and CD(133) on leukemic blasts in 76 AL patients was detected with three-color direct flow-cytometry and CD(133) mRNA was detected with hemi-quantitative reverse transcriptive polymerase chain reaction (RT-PCR).
(1) CD(34) and CD(133) expression in AL patients was significantly higher than that in controls (46.37% vs 0.47%, 21.93% vs 0.29%, P < 0.01), but there was no obvious difference of CD(90) expression between them (0.51% vs 0.25%, P > 0.05). The expression of CD(133) antigen was highly correlated with CD(133) mRNA expression in both of the normal control donors and AL patients (r = 0.932, P < 0.01). (2) The positive rates of CD(34), CD(90) and CD(133) in all AL patients were 63.2%, 7.9% and 42.1%, respectively. The expression of CD(90) in ALL was higher than that in AML (P < 0.05). Positive expression of CD(133) in AML-M(4) was significantly higher than that in other AML subtypes (P < 0.01). The positive rate of CD(34) in B-ALL was much higher than that in T-ALL (P < 0.05). (3) CD(133) expression in AML was significantly correlated with the expression of CD(34) and HLA-DR (P < 0.01). (4) The expression of CD(34), CD(90) and CD(133) was not associated with the clinical prognostic factors such as cytogenetic or molecular aberrations, initial peripheral blood WBC counts, lactate dehydrogenase level, multiple drug resistant expression and age. (5) There was a trend toward lower completely remission (CR) rate and overall survival rate in CD(34), CD(90) and CD(133) positive cases, but only CD(34)(+)/CD(133)(+) cases had significant lower CR rate than negative ones (P < 0.05).
It is indicated AL has significantly higher CD(34) and CD(133) expression as compared with the normal controls. CD(133)/CD(34) co-expression might provide adverse prognostic stratification of acute leukemia.
评估造血细胞早期分化抗原CD(34)、CD(90)和CD(133)在急性白血病（AL）中的表达及其临床意义。
采用三色直接流式细胞术检测76例AL患者白血病原始细胞上CD(34)、CD(90)和CD(133)的表达，并用半定量逆转录聚合酶链反应（RT-PCR）检测CD(133)mRNA。
（1）AL患者CD(34)和CD(133)表达显著高于对照组（46.37%对0.47%，21.93%对0.29%，P<0.01），但两者CD(90)表达无明显差异（0.51%对0.25%，P>0.05）。正常对照供者和AL患者中，CD(133)抗原表达与CD(133)mRNA表达高度相关（r=0.932，P<0.01）。（2）所有AL患者中，CD(34)、CD(90)和CD(133)的阳性率分别为63.2%、7.9%和42.1%。ALL中CD(90)表达高于AML（P<0.05）。AML-M(4)中CD(133)阳性表达显著高于其他AML亚型（P<0.01）。B-ALL中CD(34)阳性率远高于T-ALL（P<0.05）。（3）AML中CD(133)表达与CD(34)和HLA-DR表达显著相关（P<0.01）。（4）CD(34)、CD(90)和CD(133)的表达与细胞遗传学或分子异常、初始外周血白细胞计数、乳酸脱氢酶水平、多药耐药表达及年龄等临床预后因素无关。（5）CD(34)、CD(90)和CD(133)阳性病例的完全缓解（CR）率和总生存率有降低趋势，但仅CD(34)(+)/CD(133)(+)病例的CR率显著低于阴性病例（P<0.05）。
表明与正常对照相比，AL患者CD(34)和CD(133)表达显著升高。CD(133)/CD(34)共表达可能为急性白血病提供不良预后分层。
